MedTrace Logo

Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs

NCT04034862 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-03-17

No results posted yet for this study

Summary

For a few years, there has been a keen interest of clinicians and patients for "lighter" antiretroviral strategies based on two- or even single drug regimens rather than the canonical triple therapy, both as initial and maintenance therapy, despite the possibility that ongoing viral replication may occur in some patients under triple-therapy.

We will therefore propose such simplification strategy (DTG/3TC) while maintaining triple-therapy (DTG/ABC/3TC) in a control group and will perform an in depth analysis of the replication-competent reservoir in blood and in tissues as well as measurements of residual viremia and immune chronic activation/inflammation.

Conditions

  • HIV Infections

Interventions

DRUG

Treatment simplification (dolutegravir lamivudine)

Switch from 3 drug regimen (DTG/ABC/3TC) to 2 drug regimen

Sponsors & Collaborators

  • University of Liege

    lead OTHER

Principal Investigators

  • Gilles Darcis, MD PhD · Liege University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2023-03-01
Completion
2023-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04034862 on ClinicalTrials.gov